DRIO
Neutral signal
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Financial indicators Unavailable or mixed. Current ratio 3.73 · operating margin -164% — readings disagree
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
ACHAT TOTAL: 14430 titres (~100000 USD)
- Insiders
- Matheis Dennis
- Total bought
-
$100,000
Avg buy (VWAP, 90d window) $6.93 vs last close —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
- Last activity
- 2026-07-23
- Last synced
-
2026-08-04 10:23:03
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-07-23 | Matheis Dennis | Buy | 14,430 | $6.93 | $100,000 | Form 4 |
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Market snapshot
Signal
Neutral signalScored 2026-08-03
DRIO presents a genuine near-term event-driven setup — a Fortune 50 contract win, new insurer deal, GLP-1 program launch, and insider cluster buying all converge ahead of Q2 earnings on Aug 11, yielding a credible…
The first sentence of the analysis written for DRIO on 2026-08-03 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 56.6% | 49.1% | 29.4% | 34.9% | 39.3% | |
| Ebit Margin | -171.1% | -164.6% | -291.7% | -218.1% | -363.1% | |
| Ebitda Margin | -155.2% | -137.1% | -267.2% | -201.0% | -341.3% | |
| Operating Profit Margin | -163.9% | -213.6% | -276.1% | -205.4% | -372.9% | |
| Pretax Profit Margin | -186.1% | -164.9% | -291.7% | -224.9% | -374.1% | |
| Continuous Operations Profit Margin | -186.6% | -158.1% | -292.0% | -224.9% | -374.2% | |
| Net Profit Margin | -186.6% | -158.1% | -292.0% | -224.9% | -374.2% | |
| Bottom Line Profit Margin | -180.3% | -111.3% | -269.6% | -230.8% | -329.2% | |
| Current Ratio | 3.734 | 2.436 | 3.789 | 3.386 | 3.172 | |
| Quick Ratio | 3.271 | 2.151 | 3.383 | 2.975 | 2.739 | |
| Solvency Ratio | -0.905 | -0.754 | -1.424 | -1.467 | -4.750 | |
| Cash Ratio | 2.815 | 1.669 | 2.945 | 2.551 | 2.504 | |
| Price To Earnings Ratio | 9.177 | -21.243 | -17.824 | -32.548 | -56.026 | |
| Price To Earnings Growth Ratio | -0.034 | 0.345 | 0.670 | 0.753 | 3.380 | |
| Forward Price To Earnings Growth Ratio | -0.034 | 0.345 | 0.670 | 0.753 | 3.380 | |
| Price To Earnings Diluted Ratio | 9.177 | -21.243 | -17.824 | -32.548 | -56.026 | |
| Price To Earnings Diluted Growth Ratio | -0.034 | 0.345 | 0.670 | 0.753 | 3.380 | |
| Price To Book Ratio | 8.315 | 8.822 | 16.786 | 25.290 | 50.309 | |
| Price To Sales Ratio | 25.261 | 23.497 | 47.956 | 73.154 | 209.813 | |
| Price To Free Cash Flow Ratio | -21.654 | -16.418 | -31.521 | -41.785 | -84.940 | |
| Price To Operating Cash Flow Ratio | -21.772 | -16.476 | -32.127 | -42.286 | -85.379 | |
| Debt To Assets Ratio | 0.288 | 0.254 | 0.306 | 0.235 | 0.003 | |
| Debt To Equity Ratio | 0.467 | 0.419 | 0.508 | 0.351 | 0.003 | |
| Debt To Capital Ratio | 0.319 | 0.295 | 0.337 | 0.260 | 0.003 | |
| Long Term Debt To Capital Ratio | 0.312 | 0.246 | 0.297 | 0.185 | 0.000 | |
| Financial Leverage Ratio | 1.621 | 1.651 | 1.658 | 1.490 | 1.178 | |
| Working Capital Turnover Ratio | 0.906 | 0.921 | 0.502 | 0.715 | 0.703 | |
| Operating Cash Flow Ratio | -2.782 | -2.318 | -2.432 | -2.473 | -3.506 | |
| Operating Cash Flow Sales Ratio | -1.160 | -1.426 | -1.493 | -1.730 | -2.457 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.005 | 1.004 | 1.019 | 1.012 | 1.005 | |
| Debt Service Coverage Ratio | -9.183 | -6.350 | -11.838 | -4.832 | -200.140 | |
| Interest Coverage Ratio | -10.912 | -601.500 | -87.115 | -21.174 | -910.643 | |
| Short Term Operating Cash Flow Coverage Ratio | -60.328 | -7.074 | -7.683 | -5.423 | -189.508 | |
| Operating Cash Flow Coverage Ratio | -0.817 | -1.277 | -1.028 | -1.706 | -175.641 | |
| Capital Expenditure Coverage Ratio | -182.683 | -279.435 | -52.019 | -83.499 | -193.138 | |
| Dividend Paid And Capex Coverage Ratio | -182.683 | -279.435 | -52.019 | -83.499 | -193.138 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -16.439 | -17.202 | -17.815 | -36.007 | -60.959 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 56.6% | ▲7.6% | ▲14.8% |
| Ebit Margin | -171.1% | ▼-6.5% | ▲70.6% |
| Ebitda Margin | -155.2% | ▼-18.0% | ▲65.2% |
| Operating Profit Margin | -163.9% | ▲49.6% | ▲82.4% |
| Pretax Profit Margin | -186.1% | ▼-21.2% | ▲62.2% |
| Continuous Operations Profit Margin | -186.6% | ▼-28.5% | ▲60.6% |
| Net Profit Margin | -186.6% | ▼-28.5% | ▲60.6% |
| Bottom Line Profit Margin | -180.3% | ▼-69.0% | ▲43.9% |
| Current Ratio | 3.734 | ▲1.297 | ▲0.430 |
| Quick Ratio | 3.271 | ▲1.120 | ▲0.367 |
| Solvency Ratio | -0.905 | ▼-0.151 | ▲0.955 |
| Cash Ratio | 2.815 | ▲1.146 | ▲0.318 |
| Price To Earnings Ratio | 9.177 | ▲30.421 | ▲32.870 |
| Price To Earnings Growth Ratio | -0.034 | ▼-0.379 | ▼-1.057 |
| Forward Price To Earnings Growth Ratio | -0.034 | ▼-0.379 | ▼-1.057 |
| Price To Earnings Diluted Ratio | 9.177 | ▲30.421 | ▲32.870 |
| Price To Earnings Diluted Growth Ratio | -0.034 | ▼-0.379 | ▼-1.057 |
| Price To Book Ratio | 8.315 | ▼-0.507 | ▼-13.589 |
| Price To Sales Ratio | 25.261 | ▲1.763 | ▼-50.676 |
| Price To Free Cash Flow Ratio | -21.654 | ▼-5.236 | ▲17.610 |
| Price To Operating Cash Flow Ratio | -21.773 | ▼-5.296 | ▲17.836 |
| Debt To Assets Ratio | 0.288 | ▲0.035 | ▲0.071 |
| Debt To Equity Ratio | 0.467 | ▲0.048 | ▲0.118 |
| Debt To Capital Ratio | 0.319 | ▲0.023 | ▲0.076 |
| Long Term Debt To Capital Ratio | 0.312 | ▲0.066 | ▲0.104 |
| Financial Leverage Ratio | 1.621 | ▼-0.030 | ▲0.101 |
| Working Capital Turnover Ratio | 0.906 | ▼-0.015 | ▲0.156 |
| Operating Cash Flow Ratio | -2.783 | ▼-0.464 | ▼-0.080 |
| Operating Cash Flow Sales Ratio | -1.160 | ▲0.266 | ▲0.493 |
| Free Cash Flow Operating Cash Flow Ratio | 1.006 | ▲0.002 | ▼-0.004 |
| Debt Service Coverage Ratio | -9.183 | ▼-2.833 | ▲37.285 |
| Interest Coverage Ratio | -10.912 | ▲590.587 | ▲315.356 |
| Short Term Operating Cash Flow Coverage Ratio | -60.328 | ▼-53.254 | ▼-6.325 |
| Operating Cash Flow Coverage Ratio | -0.817 | ▲0.460 | ▲35.277 |
| Capital Expenditure Coverage Ratio | -182.683 | ▲96.752 | ▼-24.528 |
| Dividend Paid And Capex Coverage Ratio | -182.683 | ▲96.752 | ▼-24.528 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -16.439 | ▲0.763 | ▲13.245 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $564.8M | $635.4M | $976.0M | $2.02B | $4.30B | |
| Enterprise value | $570.3M | $637.8M | $968.7M | $2.00B | $4.27B | |
| EV / Sales | 25.51x | 23.59x | 47.60x | 72.38x | 208.07x | |
| EV / Op. cash flow | -21.98x | -16.54x | -31.89x | -41.84x | -84.67x | |
| EV / Free cash flow | -21.86x | -16.48x | -31.29x | -41.34x | -84.23x | |
| EV / EBITDA | -16.44x | -17.20x | -17.82x | -36.01x | -60.96x | |
| Net debt / EBITDA | -0.16x | -0.07x | 0.13x | 0.38x | 0.51x | |
| Current ratio | 3.73x | 2.44x | 3.79x | 3.39x | 3.17x | |
| Income quality | 0.62x | 0.90x | 0.51x | 0.77x | 0.66x | |
| Graham net-net | -$0 | -$0 | $0 | $1 | $2 | |
| Tax burden | 100.3% | 95.8% | 100.1% | 100.0% | 100.0% | |
| Interest burden | 108.8% | 100.2% | 100.0% | 103.1% | 103.0% | |
| Working capital | $25.5M | $23.9M | $34.8M | $46.2M | $31.2M | |
| Invested capital | $100.1M | $101.9M | $83.7M | $99.7M | $86.3M | |
| Return on assets | -37.9% | -36.0% | -61.7% | -52.2% | -76.2% | |
| Operating ROA | -32.0% | -53.6% | -52.1% | -51.7% | -112.3% | |
| Return on tangible assets | -113.6% | -100.1% | -120.4% | -92.0% | -164.5% | |
| Return on equity | -61.4% | -59.4% | -102.2% | -77.7% | -89.7% | |
| Return on invested capital | -36.2% | -51.1% | -63.9% | -52.1% | -88.3% | |
| Return on capital employed | -36.4% | -56.5% | -67.0% | -56.9% | -88.5% | |
| Earnings yield | -7.4% | -6.7% | -6.1% | -3.1% | -1.8% | |
| Free cash flow yield | -4.6% | -6.1% | -3.2% | -2.4% | -1.2% | |
| Capex / Op. cash flow | -0.5% | -0.4% | -1.9% | -1.2% | -0.5% | |
| Capex / Depreciation | 5.0% | 1.9% | 11.7% | 12.1% | 5.9% | |
| Capex / Sales | 0.6% | 0.5% | 2.9% | 2.1% | 1.3% | |
| SG&A / Sales | 158.9% | 173.2% | 205.4% | 169.3% | 304.0% | |
| R&D / Sales | 61.7% | 89.4% | 99.5% | 71.0% | 83.9% | |
| Stock comp / Sales | 41.9% | 58.4% | 96.8% | 61.4% | 121.7% | |
| Intangibles / Total assets | 66.6% | 64.1% | 48.8% | 43.3% | 53.7% | |
| Days sales outstanding | 44d | 72d | 65d | 85d | 32d | |
| Days payables outstanding | 110d | 81d | 29d | 47d | 150d | |
| Operating cycle | 206d | 198d | 194d | 246d | 214d | |
| Cash conversion cycle | 96d | 118d | 165d | 199d | 65d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-11.1%EV / Sales ▲+8.1%EV / EBITDA ▲+4.4%EV / Op. cash flow ▼-5.445Earnings yield ▼-0.007
Profitability
Return on equity ▼-0.021Return on assets ▼-0.019Return on invested capital ▲+0.149Return on capital employed ▲+0.201Operating ROA ▲+0.216Income quality ▼-0.280Tax burden ▲+0.044
Efficiency
Days sales outstanding ▼-28.641Days payables outstanding ▲+29.550Operating cycle ▲+7.906Cash conversion cycle ▼-21.644Capex / Sales ▲+0.001R&D / Sales ▼-0.277
Balance-sheet strength
Current ratio ▲+1.297Net debt / EBITDA ▼-0.093Working capital ▲+1592000.000Invested capital ▼-1747000.000Intangibles / Total assets ▲+0.026
Change over 5 years
Valuation
Market cap ▼-86.9%EV / Sales ▼-87.7%EV / EBITDA ▲+73.0%EV / Op. cash flow ▲+62.686Earnings yield ▼-0.056
Profitability
Return on equity ▲+0.283Return on assets ▲+0.383Return on invested capital ▲+0.520Return on capital employed ▲+0.522Operating ROA ▲+0.803Income quality ▼-0.035Tax burden ▲+0.002
Efficiency
Days sales outstanding ▲+11.823Days payables outstanding ▼-39.609Operating cycle ▼-8.346Cash conversion cycle ▲+31.263Capex / Sales ▼-0.006R&D / Sales ▼-0.223
Balance-sheet strength
Current ratio ▲+0.561Net debt / EBITDA ▼-0.669Working capital ▼-5743000.000Invested capital ▲+13792000.000Intangibles / Total assets ▲+0.130
Employee count
Peer market caps
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent news
- 2026-08-03 DarioHealth to Report Second Quarter 2026 Results on Tuesday, August 11, 2026 Company to host conference call and webcast at 8:30 a.m. Eastern Time NEW YORK, Aug. 3, 2026 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leading artificial intelligence ("AI")-powered healthcare technology company transforming the management of chronic conditions, announced today that it will release its financial results for the 2nd quarter ended June 30th, 2026 and will host a conference call and webcast at 8:30 a.m.
- 2026-07-30 Dario Launches Integrated GLP-1 Program, Combining Its Digital Chronic Care Platform with Provider-Backed Clinical Care in a Single End-to-End Experience First commercial offering from Dario''s collaboration with Beluga Health adds licensed provider evaluation, prescribing and ongoing clinical oversight directly inside Dario''s chronic care platform Commercial availability expected Fall 2026, with revenue contribution anticipated late 2026 and ramping through 2027 Launch addresses a market in which employers and health plans are reducing GLP-1 coverage and members are increasingly accessing care through consumer channels Available through three channels: Dario''s direct-to-consumer shop, health plan marketplaces and employer B2B2C programs NEW YORK, July 30, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced the launch of Dario''s Integrated GLP-1 Program, the first commercial offering built on the Company''s recently announced collaboration with Beluga Health ("Beluga"). Dario has supported members on GLP-1 therapy for years through AI-powered engagement, connected monitoring, nutrition and behavioral coaching.
- 2026-07-23 DarioHealth (DRIO) Moves 12.9% Higher: Will This Strength Last? DarioHealth (DRIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn''t suggest further strength down the road.
- 2026-07-22 Dario Announces Pricing of a $23.5 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules The financing was led by continued support of existing long-term institutional investors along with participation from a new global fundamental institutional investor NEW YORK, July 22, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company," "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced that it has entered into securities purchase agreements with current long term Dario institutional investors as well as new fundamental investors for the purchase and sale of 3,454,559 shares of common stock (or common stock equivalents in lieu thereof), at a price of $6.80 per share, in a registered direct offering priced at-the-market under Nasdaq rules (the "Offering"). A member of the Company''s Board of Directors participated in the Offering by purchasing 14,430 shares of the Company''s common stock at a purchase price of $6.93 per share.
- 2026-07-22 Financial Analysis: Echo Therapeutics (OTCMKTS:ECTE) vs. DarioHealth (NASDAQ:DRIO) DarioHealth (NASDAQ: DRIO - Get Free Report) and Echo Therapeutics (OTCMKTS:ECTE - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation and institutional ownership. Institutional and Insider Ownership 33.4% of DarioHealth shares are
- 2026-07-16 Fortune 50 Employer Awards Dario Contract to Deliver AI-Powered Cardiometabolic Care Platform Contract award for over 100,000 eligible employees marks Dario''s fifth Fortune 50 client, further reflecting growing demand among large employers for integrated, outcomes-driven chronic condition management Program expected to launch Fall 2026, with revenue contribution beginning by year-end and ramping through 2027 NEW YORK, July 16, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced another Fortune 50 employer has selected Dario to provide its integrated digital cardiometabolic care platform for employees living with diabetes and/or hypertension. The program will be available to more than 100,000 eligible employees and is expected to launch in Fall 2026.
- 2026-07-13 Dario Expects Proprietary AI Engine DarioIQ™ to Increase Recurring Revenue from Existing Customers by 10-15% DarioIQ drives higher engagement and retention, better clinical outcomes, higher client ROI and recurring revenue growth for Dario Dario IQ''s AI-driven personalization increases member engagement by 40% and improves member retention by 20% by leveraging 13+ billion proprietary real-world healthcare data points NEW YORK, July 13, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company," "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced the Company expects broader deployment of DarioIQ™, its proprietary, responsible generative and agentic AI platform, to increase annual Business-to-Business-to-Consumer ("B2B2C") recurring revenue by approximately 10% to 15% from existing customers, before the impact of future customer wins or additional condition expansions. While Dario continues to demonstrate success with its land-and-expand strategy with existing enterprise customers through its multi-condition platform, DarioIQ creates an additional opportunity to lift B2B2C annual recurring revenues from current clients.
- 2026-07-06 Dario Signs New Agreement with a Major Health Insurer in Arizona Representing Hundreds of Thousands of Lives Through Amwell Partnership Agreement representative of Dario''s channel-led growth strategy to bring cardiometabolic digital health solution at scale to self-insured employers seeking measurable reductions in cardiometabolic risk and total cost of care via payer relationships NEW YORK, July 6, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced a new agreement with a major health insurer with a stronghold in Arizona, entered into through its strategic channel partnership with Amwell. This opportunity makes Dario''s cardiometabolic solution available to the insurer''s Administrative Services Only ("ASO") book of business, representing access to hundreds of thousands of covered lives.
- 2026-07-02 Top National Health Plan Extends Agreement for Mental Health and Expands Dario Partnership into Cardiometabolic Care, Demonstrating Successful Multi-Condition Growth Strategy Top National Health Plan Extends Agreement for Mental Health and Expands Dario Partnership into Cardiometabolic Care, Demonstrating Successful
- 2026-07-02 Top National Health Plan Extends Agreement for Mental Health and Expands Dario Partnership into Cardiometabolic Care, Demonstrating Successful Multi-Condition Growth Strategy Third health plan customer to expand beyond initial deployment, reinforcing Dario''s land-and-expand strategy and creating significant opportunity to grow revenue within existing customer base NEW YORK, July 2, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in AI-powered digital health solutions, today announced that one of the 5 largest health insurers in the U.S. has extended its initial agreement and expanded its relationship with Dario by adding the Company''s hypertension solution, following success with Dario''s behavioral health offering. The health plan''s roll out of Dario''s cardiometabolic care significantly increases the addressable population and has the potential to approximately triple Dario''s revenue opportunity under this customer relationship.